

SUPPORTING INFORMATION FOR

Quinoidal Tetrazines: Formation of a Fascinating Compound Class

Beatrix Bostai,^a Zoltán Novák,^a Attila C. Bényei,^b András Kotschy^{a,*}

^a Institute of Chemistry, Eötvös Loránd University, Pázmány Péter s. 1/A, H-1117 Budapest, Hungary

^b Laboratory of X-ray Diffraction, Department of Chemistry, University of Debrecen, H-4010 Debrecen, P.O.Box 7., Hungary


TABLE OF CONTENTS

GENERAL EXPERIMENTAL	S2
PREPARATION OF NHC PRECURSORS	S2
1,3-Dimethyl-benzimidazolium iodide (2h):	S2
1,3-Dibenzyl-benzimidazolium chloride (2i):	S3
1,3-Bis(1'-phenylethyl)-benzimidazolium bromide (2j):	S3
1,3-Dibenzyl-3a,4,5,6,7,7a-hexahydro-benzimidazolium tetrafluoroborate (2k):	S4
1,3,4-Triphenyl-4H-[1,2,4]-triazolium tetrafluoroborate (2l):	S4
GENERAL PROCEDURE FOR THE PREPARATION OF QUINOIDAL TETRAZINES	S4
6-[1,3-Bis(mesityl)-1,3-dihydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3a):	S5
UV-VIS experiments for the determination of negative solvatochromism of non-zwitter-ionic tetrazine compounds:	S6
Crystallographic Characterization of 3a.	S6
6-[1,3-Bis(mesityl)-1,3,4,5-tetrahydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3b):	S7
6-(1-Butyl-3-methyl-1,3-dihydro-imidazol-2-ylidene)-6H-[1,2,4,5]tetrazine-3-one (3c):	S8
6-(1,3-Dibutyl-1,3-dihydro-imidazol-2-ylidene)-6H-[1,2,4,5]tetrazine-3-one (3d):	S8
6-[1-Mesityl-3-(1'R-1'-phenylethyl)-1,3,4,5-tetrahydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3e):	S9
6-[1,3-Bis(1'R-1'-phenylethyl)-1,3,4,5-tetrahydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3f):	S9
6-[1,3-Bis(1'R-1'-phenylethyl)-1,3-dihydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3g):	S10
6-(1,3-Dimethyl-1,3-dihydro-benzimidazol-2-ylidene)-6H-[1,2,4,5]tetrazin-3-one (3h):	S11
6-(1,3-Dibenzyl-1,3-dihydro-benzimidazol-2-ylidene)-6H-[1,2,4,5]tetrazin-3-one (3i):	S11
6-[1,3-Bis(1-phenylethyl)-1,3-dihydro-benzimidazol-2-ylidene]-6H-[1,2,4,5]tetrazin-3-one (3j):	S12
6-(1,3-Dibenzyl-1,3,3a,4,5,6,7,7a-octahydro-benzimidazol-2-ylidene)-6H-[1,2,4,5]tetrazine-3-one (3k):	S12
6-(2,4,5-Triphenyl-2,4-dihydro-[1,2,4]triazol-3-ylidene)-6H-[1,2,4,5]tetrazine-3-one (3l):	S13
1H and 13C NMR spectra of 3a-l	S14

GENERAL EXPERIMENTAL

All reactions were carried out under an atmosphere of dry argon or nitrogen using standard Schlenk techniques. Solvents were acquired from commercial sources, acetonitrile was dried over CaH_2 , tetrahydrofuran over potassium and both were freshly distilled under argon before use. Reagents were either purchased from commercial sources and used without further purification, unless indicated otherwise, or prepared according to the literature. Thin layer chromatography (TLC, normal phase) was visualized by UV light (254nm) while column chromatography purification was carried out on Merck Silicagel (0.040–0.063 mm). NMR spectra were recorded on a Bruker AC 250 MHz or DRX 200 MHz spectrometer using standard Bruker sequences. The chemical shifts (δ) for ^1H and ^{13}C are given in ppm referenced to the residual signal of the deuterated solvent. MS spectra were measured on a PE Sciex API-2000 spectrometer. Exact masses were determined on a Q-Star Pulsar (Applied Biosystems) quadrupole-time-of-flight spectrometer (ESI+, capillary 6000V, declustering potential: 20V). IR spectra were recorded on a Brucker IFS-55 spectrophotometer in KBr pastille. UV-VIS spectra were recorded on a Varian CARY 3E spectrophotometer in methanol, except for **2a**, where other solvents (methanol-water (1:1), chloroform, acetonitrile, dichloromethane) were also used. X-ray structures were analyzed on a Bruker Nonius MACH3 diffractometer. Determination of α_D values for compounds **3e**, **3f**, **3g** and **3j** cannot be achieved by optical rotation measurement due to their highly colored (violet) solutions (their absorption are in the same range as the applicable light sources). All melting points were measured on Büchi 501 apparatus and are uncorrected.

PREPARATION OF NHC PRECURSORS¹




1,3-Dimethyl-benzimidazolium iodide (2h):

1.020 g (8.6 mmol) benzimidazole was dissolved in 10 ml 5N KOH solution and 5 ml MeOH, and 6 ml (96.4 mmol) MeI (99%) was added dropwise. Temperature was kept about 45°C, and

¹ NHC precursors **2a-g**, are either commercially available or were prepared according to literature procedures. For references see the manuscript.

the precipitated solid was filtered, and recrystallized from methanol-water mixture. 1.702 g **2h** was obtained as white solid (72% yield).


¹H NMR (250 MHz, d₆-DMSO) 9.66 (s, 1H); 8.04-8.00 (m, 2H); 7.72-7.68 (m, 2H); 4.08 (s, 6H). ¹³C NMR (62.9 MHz, d₆-DMSO) 143.0; 131.5; 126.3; 113.1; 33.2. mp: 190-191°C (measured); 189-192°C (literature)².



1,3-Dibenzyl-benzimidazolium chloride (2i):

2.000 g (16.93 mmol) benzimidazole was stirred in 6 mL benzyl chloride at 120°C for 2 days. The mixture was treated with hot ethanol, and after cooling to ambient temperature the precipitated white solid was filtered (2.385 g, 42% yield).

¹H NMR (250 MHz, CDCl₃ and d₆-DMSO) 10.50 (s, 1H); 8.03-7.96 (m, 2H); 7.65-7.29 (m, 6H); 7.45-7.36 (m, 6H); 5.85 (s, 4H). ¹³C NMR (50.3 MHz, CD₃OD and d₆-DMSO) 142.3; 133.2; 132.1; 130.0; 129.9; 128.6; 128.1; 114.4; 51.9. mp: 210-211°C (measured); 210-211°C (literature)³.




1,3-Bis(1'-phenylethyl)-benzimidazolium bromide (2j):

1.000 g (8.5 mmol) benzimidazole was stirred with 0.459 g (8.5 mmol) sodium methoxide in 6 mL toluene at 94°C. After 25 minutes, 5.26 ml (37 mmol) (1-bromoethyl)-benzene (rac.) was added. The mixture was heated for 2 days, after which it was diluted with ethanol and cooled to ambient temperature. The precipitated white solid (sodium bromide) was filtered. The filtrate was evaporated, and the mixture was purified by column chromatography using dichloromethane-methanol (9:1). **2j** was crystallized from dichloromethane-diethyl ether. Product is white solid (0.856 g, 25% yield). **2j** was obtained as a mixture of diastereoisomers. ¹H NMR (200 MHz, CDCl₃) 11.95 (d, 1H, J = 5.8 Hz); 7.54-7.50 (m, 4H); 7.42-7.33 (m, 10H); 6.33-6.30 (m, 2H); 2.33 (d, 6H, J = 6.2 Hz). ¹³C NMR (50.3 MHz, CDCl₃) 141.6; 141.5;

² Khristich, B. I.; Bondarenko, E. V. *Chem. Heterocycl. Compd.* **1987**, 23, 284.

³ Starikova, O.V.; Dolgushin, G. V.; Larina, L.I.; Ushakov, P.E.; Komarova, T. N.; Lopyrev, V. A. *Russ. J. Org. Chem.* **2003**, 10, 1467.


137.5; 137.5; 131.1; 131.0; 129.4; 129.0; 128.9; 128.1; 126.8; 126.7; 114.6; 59.4; 59.3; 21.2; 21.1. mp: 185- 187°C (measured).



1,3-Dibenzyl-3a,4,5,6,7,7a-hexahydro-benzimidazolium tetrafluoroborate (2k):

1.568 g (5.4 mmol) *N,N'*-dibenzyl-cyclohexane-1,2-diamine⁴ and 0.567 g (5.4 mmol) ammonium tetrafluoroborate was stirred in 30 ml triethyl ortoformate at 120°C for 4 hours. The solvent was evaporated and the off-white residue was crystallized from ethanol to give 1.195 g **2k** (57% yield) as a white solid.

¹H NMR (250 MHz, CDCl₃) 8.67 (s, 1H); 7.36-7.29 (m, 10H); 4.72 (s, 4H); 3.33 (t, 2H, *J* = 4.3 Hz); 2.03-1.95 (m, 2H); 1.72-1.69 (m, 2H); 1.29-1.06 (m, 4H). ¹³C NMR (62.9 MHz, CDCl₃) 160.1; 132.8; 128.8; 128.4; 128.1; 67.3; 50.6; 27.1; 23.1. mp.: 146-147°C (measured).



1,3,4-Triphenyl-4H-[1,2,4]-triazolium tetrafluoroborate (2l):

The synthetic procedure did partially deviate from the literature.^{5,6} 5.740 g (0.020 mol) *N*-phenyl-benzamide phenyl-hydrazone and 2.096 g (0.020 mol) ammonium tetrafluoroborate were heated in 60 ml triethyl ortoformate at 120°C for 12 h. After cooling to room temperature the precipitated solid was filtered and washed with distilled water and diethyl ether. We obtained 5.802 g of **2l** (76% yield) as white solid.

¹H NMR (250 MHz, d₆-DMSO) 11.38 (s, 1H); 8.11 (d, 2H, *J* = 7.8 Hz); 7.83-7.61 (m, 9H); 7.56-7.54 (m, 4H). ¹³C NMR (62.9 MHz, d₆-DMSO) 153.2; 143.1; 134.8; 132.2; 132.0; 131.5; 130.8; 130.3; 130.1; 129.2; 129.2; 126.5; 122.3; 120.5. mp.: 171°C (measured).

GENERAL PROCEDURE FOR THE PREPARATION OF QUINOIDAL TETRAZINES


A glass vial was charged with the carbene precursor, potassium carbonate and dry acetonitrile as solvent, purged with argon, sealed and heated to 75-80°C for 40 min. The solution of 3,6-

⁴ Denmark,S.E., Stadler, H., Dorow, R. L., Kim, J-H. *J. Org. Chem.*, **1991**, *56*, 5063.

⁵ Enders D., Breuer K., Kallfass U., Ballensiefer T. *Synthesis*, **2003**, 1292.

⁶ Trnka, T. M.; Morgan, J. P.; Sanford, M. S.; Wielhelmi, T. E.; Scholl, M.; Choi, T-L.; Ding, S.; Day, M. W.; Grubbs, R. H. *J. Am. Chem. Soc.* **2003**, *125*, 2546.

bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine⁷ (**1**) in degassed dry acetonitrile was added to the solution of the free carbene, using a canula. The mixture was stirred at 75–80°C until the consumption of **1** by TLC (eluent: methanol-ethyl acetate (1:4) or dichloromethane-methanol (10:1)). Reaction times were ranging from a few hours in the cases of **2a-h**, to one or two days using **2i-2l** as starting material. After cooling to room temperature and removal of the solvent under reduced pressure the residue was purified by column chromatography (eluent: methanol: ethyl acetate (1:4)), except of **3h**.




6-[1,3-Bis(mesityl)-1,3-dihydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3a):

From 196 mg (0.5 mmol) 3-bis(mesityl)-imidazolium tetrafluoroborate (**2a**), 69 mg (0.5 mmol) dry K₂CO₃ in 3 mL acetonitrile, and 135 mg (0.5 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine in 3 mL acetonitrile we obtained 192 mg **3a** (96% yield) as a violet solid following column chromatography.

¹H NMR (250 MHz, d₆-DMSO) 8.41 (s, 2H); 7.10 (s, 4H); 2.30 (s, 6H); 2.05 (s, 12H). ¹³C NMR (62.9 MHz, CDCl₃) 161.2; 143.8; 143.2; 141.3; 134.4; 130.8; 129.7; 124.1; 21.1; 17.4. HRMS (ESI-QTOF) calcd for [C₂₃H₂₅N₆O]⁺, [MH]⁺: 401.2089 found 401.2089, difference: 0.0 ppm. MS (ESI, scan); m/z (%): 401 [MH]⁺; 330 [88%]; 145 [13%]; 119 [25%]; 91 [25%]. IR (KBr, cm⁻¹): 3165 (m), 3099 (m), 2921 (m), 2856 (m), 2142 (w), 1988 (w), 1643 (s), 1611 (s), 1564 (s), 1498 (s), 1383 (m), 1263 (m), 1233 (s), 1035 (m), 996 (m), 865 (m), 786 (m), 741 (m), 575 (m), 434 (w). UV-VIS (300 nm-800 nm, 1 = 1 cm): λ_{max,Vis}=560 nm, ε = 358 dm³*mol⁻¹*cm⁻¹ (methanol, c = 1.07*10⁻³ mol*dm⁻³), λ_{max,Vis} = 557 nm, ε = 391 dm³*mol⁻¹*cm⁻¹ (methanol-water (1:1), c = 4.63*10⁻⁴ mol*dm⁻³), λ_{max,Vis} = 567 nm, ε = 405 dm³*mol⁻¹*cm⁻¹ (chloroform, c = 8.81*10⁻⁴ mol*dm⁻³), λ_{max,Vis} = 568 nm, ε=362 dm³*mol⁻¹*cm⁻¹ (acetonitrile, c = 7.70*10⁻⁴ mol*dm⁻³), λ_{max,Vis} = 572 nm, ε = 368 dm³*mol⁻¹*cm⁻¹ (dichloromethane, c = 1.35*10⁻³ mol*dm⁻³); Δλ_{max,Vis} = 15 nm (5 solvents). mp: 253°C (decomp.).

⁷ Coburn, M. D.; Buntain, G. A.; Harris, B. W.; Hiskey, M. A.; Lee;K. Y.; Ott, D. G.; *J. Heterocycl. Chem.* **1991**, 28, 2049



UV-VIS experiments for the determination of negative solvatochromism of non-zwitterionic tetrazine compounds:

3,6-Bis(3,5-dimethyl-pyrazol-1-yl)-1,2,4,5-tetrazine: UV-VIS (300-800nm, l=1cm): λ_{max} , $\text{vis} = 521\text{nm}$, $\epsilon = 370\text{dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$ (methanol, $c = 9.32 * 10^{-4} \text{ mol}*\text{dm}^{-3}$), $\lambda_{\text{max, vis}} = 524\text{nm}$, $\epsilon = 360 \text{ dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$ (acetonitrile, $c = 1.34 * 10^{-3} \text{ mol}*\text{dm}^{-3}$), $\lambda_{\text{max, vis}} = 533 \text{ nm}$, $\epsilon = 405 \text{ dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$ (dichloromethane, $c = 1.40 * 10^{-3} \text{ mol}*\text{dm}^{-3}$), $\lambda_{\text{max, vis}} = 535 \text{ nm}$, $\epsilon = 474 \text{ dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$ (chloroform, $c = 1.36 * 10^{-3} \text{ mol}*\text{dm}^{-3}$), $\Delta\lambda_{\text{max, vis}} = 14 \text{ nm}$.


3,6-Di(pyridin-3-yl)-1,2,4,5-tetrazine: $\lambda_{\text{max, vis}} = 538 \text{ nm}$, $\epsilon = 384 \text{ dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$ (methanol, $c = 1.03 * 10^{-3} \text{ mol}*\text{dm}^{-3}$), $\lambda_{\text{max, vis}} = 538 \text{ nm}$, $\epsilon = 369 \text{ dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$ (acetonitrile, $c = 1.57 * 10^{-3} \text{ mol}*\text{dm}^{-3}$), $\lambda_{\text{max, vis}} = 548\text{nm}$, $\epsilon = 317 \text{ dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$ (dichloromethane, $c = 1.25 * 10^{-3} \text{ mol}*\text{dm}^{-3}$), $\lambda_{\text{max, vis}} = 550 \text{ nm}$, $\epsilon = 474 \text{ dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$ (chloroform, $c = 1.17 * 10^{-3} \text{ mol}*\text{dm}^{-3}$), $\Delta\lambda_{\text{max, vis}} = 12 \text{ nm}$.

Crystallographic Solution and Refinement Details

Crystallographic Characterization of **3a**.

Single crystals were grown by very slow evaporation of ethanol solution of **3a**. Purple block (0.45 x 0.35 x 0.3 mm) crystals of $\text{C}_{23}\text{H}_{24}\text{N}_6\text{O}$, $M = 400.48$, monoclinic, $a = 11.7079(10) \text{ \AA}$, b

$a = 15.3735(10)$ Å, $c = 11.8425(10)$ Å, $\beta = 90.76(1)$, $V = 2131.4(3)$ Å³, $Z = 4$, space group: P2₁/n (No. 14), $\rho_{\text{calc}} = 1.248$ g cm⁻³. Data were collected at 293(1) K, Enraf Nonius MACH3 diffractometer, Mo K α radiation $\lambda = 0.71073$ Å, ω -2 θ motion, $\theta_{\text{max}} = 25.97^\circ$, 3971 measured, 2258 reflections were unique with $I > 2\sigma(I)$, decay: none. The structure was solved using the SIR-92 software⁸ and refined on F² using SHELLX-97 program⁹, publication material was prepared with the WINGX-97 suite¹⁰, $R(F) = 0.0629$ and $wR(F^2) = 0.2407$ for 3971 reflections, 277 parameters. Residual electron density: 0.217/-0.275 e/Å³. Anisotropic refinement of non hydrogen atoms. Aromatic hydrogen atoms were placed into geometric positions while orientation of methyl groups were refined using a riding model. Additional crystallographic information is provided in the deposited CIF.



6-[1,3-Bis(mesyl)-1,3,4,5-tetrahydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3b):


From 242 mg (0.6 mmol) 1,3-bis(mesyl)-4,5-dihydro-imidazolium tetrafluoroborate (**2b**), 84 mg (0.6 mmol) K₂CO₃ in 7 mL acetonitrile, and 162 mg (0.6 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 7 mL acetonitrile we obtained 232 mg **3b** (95% yield) as violet solid following column chromatography.

¹H NMR (250 MHz, CDCl₃ + CD₃CN) 6.88 (s, 4H); 4.41 (s, 4H); 2.29 (s, 12H); 2.24 (s, 6H). ¹³C NMR (62.9 MHz, CDCl₃ + CD₃OD) 162.3; 161.4; 144.8; 140.2; 134.7; 130.9; 129.7; 50.5; 20.6; 17.2. HRMS (ESI-QTOF) calcd for [C₂₃H₂₇N₆O]⁺, [MH]⁺: 403.2241, found 403.2232, difference: 2.2 ppm. MS/MS (ESI, scan): *m/z* (%): 403 [MH⁺, 45%]; 375 [4%]; 332 [100%]. IR (KBr, cm⁻¹) 2969 (w), 2917 (m), 2859 (w), 1663 (s), 1652 (s), 1633 (s), 1610 (s), 1560 (vs), 1479 (m), 1379 (m), 1292 (s), 1275 (m), 1262 (s), 1222 (m), 1016 (m), 994 (m), 855 (w), 573 (m), 429 (w). UV-VIS (300 nm-800 nm, $l = 1$ cm, methanol, $c = 4.89 \times 10^{-6}$ mol*dm⁻³) $\lambda_{\text{max,Vis}} = 559$ nm, $\epsilon = 385$ dm³*mol⁻¹*cm⁻¹. mp: 236-237°C (decomp.).

⁸ A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, *J. Appl. Cryst.* **1993**, 26, 343–350.

⁹ Programs for Crystal Structure Analysis (Release 97-2). Sheldrick, G.M., Institut für Anorganische Chemie der Universität, Tammanstrasse 4, D-3400 Göttingen, Germany, **1998**.


¹⁰ L. J. Farrugia, *J. Appl. Cryst.* **1999**, 32, 837-838.



6-(1-Butyl-3-methyl-1,3-dihydro-imidazol-2-ylidene)-6H-[1,2,4,5]tetrazine-3-one (3c):

From 99 mg (0.4 mmol) 1-butyl-3-methyl-imidazolium hexafluorophosphate (**2c**), 56 mg (0.4 mmol) K₂CO₃ in 3.5 mL acetonitrile, and 107 mg (0.4 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 3.5 mL acetonitrile we obtained 93 mg **3c** (99% yield) as violet solid following column chromatography.

¹H NMR (250 MHz, d₆-DMSO) 7.94 (d, 1H, *J* = 2.0 Hz); 7.88 (d, 1H, *J* = 2.0 Hz); 4.33 (t, 2H, *J* = 7.3 Hz); 3.93 (s, 3H); 1.80-1.68 (m, 2H); 1.28-1.16 (m, 2H); 0.84 (t, 3H, *J* = 7.0 Hz). ¹³C NMR (62.9 MHz, d₆-DMSO) 160.6; 144.9; 139.1; 124.2; 122.6; 48.8; 36.9; 31.5, 18.7; 13.1 HRMS (ESI-QTOF) calcd for [C₁₀H₁₅N₆O]⁺, [MH]⁺: 235.1301, found 235.1302, difference: 0.06 ppm. MS (ESI, scan) *m/z* (%): 235 [MH⁺, 10%]; 164 [70%]; 108 [43%]. IR (KBr, cm⁻¹) 3112 (m), 3083 (m), 2964 (m), 2939 (m), 2869 (s), 1987 (s), 1636 (w), 1605 (w), 1587 (w), 1526 (m), 1384 (s), 1251 (m), 991 (m), 839 (s), 796 (s), 575 (s). UV-VIS (300 nm-800 nm, l = 1 cm, methanol, c = 2.15*10⁻³ mol*dm⁻³) $\lambda_{\text{max,Vis}} = 556 \text{ nm}$, $\varepsilon = 312 \text{ dm}^3*\text{mol}^{-1}*\text{cm}^{-1}$. mp: 185-186°C (decomp.).




6-(1,3-Dibutyl-1,3-dihydro-imidazol-2-ylidene)-6H-[1,2,4,5]tetrazine-3-one (3d):

From 160 mg (0.6 mmol) 1,3-dibutyl-imidazolium bromide (**2d**), 83 mg (0.6 mmol) K₂CO₃ in 7 mL acetonitrile, and 162 mg (0.6 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 7 mL acetonitrile we obtained 161 mg **3d** (97% yield) as violet waxy-solid following column chromatography.

¹H NMR (250 MHz, CDCl₃) 7.79 (s, 2H); 4.32 (t, 4H, *J* = 7.5 Hz); 1.76-1.64 (m, 4H); 1.25-1.10 (m, 4H); 0.73 (t, 6H, *J* = 7.3 Hz). ¹³C NMR (62.5 MHz, CDCl₃) 161.7; 144.9; 139.0; 123.0; 49.7; 31.9; 19.1; 13.0. HRMS (ESI-QTOF) calcd for [C₁₃H₂₁N₆O]⁺, [M+H]⁺: 277.1771, found 277.1758, difference: 4.6 ppm. MS (ESI, scan) *m/z* (%): 277 [MH⁺ 35%,]; 206 [50%]; 150 [25%]; 94 [10%]. IR (KBr, cm⁻¹) 3110 (m), 3077 (m), 2960 (s), 2933 (s), 2874 (m), 1988


(w), 1640 (s), 1607 (s), 1580 (s), 1514 (m), 1460 (m), 1385 (m), 1253 (s), 993 (m), 837 (w), 795 (w), 574 (w). UV-VIS (300 nm-800 nm, $l = 1$ cm, methanol, $c = 1.87 \text{ mol} \cdot \text{dm}^{-3}$) $\lambda_{\max, \text{Vis}} = 557 \text{ nm}$, $\epsilon = 245 \text{ dm}^3 \cdot \text{mol}^{-1} \cdot \text{cm}^{-1}$.



6-[1-Mesyl-3-(I'R-1'-phenylethyl)-1,3,4,5-tetrahydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3e):

From 140 mg (0.37 mmol) 1-mesyl-3-(I'R-1'-phenylethyl)-4,5-dihydro-imidazolium tetrafluoroborate (**2e**), 52 mg (0.37 mmol) K_2CO_3 in 5 mL acetonitrile, and 100 mg (0.37 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 5 mL acetonitrile we obtained 110 mg **3e** (77% yield) as violet solid following column chromatography.

^1H NMR (250 MHz, CDCl_3) 7.39 (s, 5H); 6.80 (s, 1H); 6.76 (s, 1H); 5.85 (q, 1H, $J = 7.3 \text{ Hz}$); 4.55-3.75 (m, 4H); 2.19 (s, 6H); 2.14 (s, 3H); 1.80 (d, 3H, $J = 7.0 \text{ Hz}$). ^{13}C NMR (62.9 MHz, CDCl_3) 161.0, 144.5, 139.8, 136.2, 135.2, 131.5, 129.6, 129.2, 128.9, 126.9, 55.9, 49.7, 43.9, 20.8, 17.7, 17.5, 16.4. HRMS (ESI-QTOF) calcd for $[\text{C}_{22}\text{H}_{25}\text{N}_6\text{O}]^+$, $[\text{MH}]^+$: 389.2084, 389.2076, difference: 2.3 ppm. MS (ESI, scan); m/z (%): 389 [MH^+ , 41%]; 285 [100%]; 214 [58%]. IR (KBr, cm^{-1}) 2978 (w), 2924 (w), 2855 (w), 2024 (w), 1656 (vs), 1608 (vs), 1566 (vs), 1484 (w), 1379 (m), 1294 (m), 1257 (m), 1015 (m), 833 (w), 760 (w), 580 (m). UV-VIS (300 nm-800 nm, $l = 1$ cm, methanol, $c = 8.73 \cdot 10^{-4} \text{ mol} \cdot \text{dm}^{-3}$) $\lambda_{\max, \text{Vis}} = 558 \text{ nm}$, $\epsilon = 319 \text{ dm}^3 \cdot \text{mol}^{-1} \cdot \text{cm}^{-1}$. mp: 198-200°C (decomp.).




6-[1,3-Bis(I'R-1'-phenylethyl)-1,3,4,5-tetrahydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (3f):

From 37 mg (0.1 mmol) 1,3-bis(I'R-1'-phenylethyl)-4,5-dihydro-3H-imidazolium tetrafluoroborate (**2f**), 14 mg (0.1 mmol) K_2CO_3 in 3 ml acetonitrile, and 27 mg (0.1 mmol)

3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 3 mL acetonitrile we obtained 34 mg **3f** (90%) as violet solid following column chromatography.


¹H NMR (250 MHz, CDCl₃) 7.32-7.16 (m, 10H); 5.48 (q, 2H, *J* = 7.0 Hz); 3.92-3.77 (m, 2H); 3.62-3.48 (m, 2H); 1.65 (d, 6H, *J* = 7.0 Hz). ¹³C NMR (62.9 MHz, CDCl₃) 161.2; 159.9; 144.2; 136.3; 129.3; 129.1; 127.0; 55.9; 42.8; 16.5. HRMS (ESI-QTOF) calcd for [C₂₁H₂₃N₆O]⁺, [MH]⁺: 375.1927, found 375.1920, difference: 2.32 ppm. MS/MS (ESI, scan); *m/z* (%): 375 [MH⁺, 41%]; 304 [100 %]. IR (KBr, cm⁻¹) 3056 (w), 2975 (w), 2929 (w), 2007 (w), 1698 (sh), 1653 (s), 1588 (s), 1575 (s), 1558 (s), 1496 (s), 1285 (s), 1254 (m), 1221 (m), 1191 (m), 1147 (m), 1026 (m), 1006 (m), 758 (m), 700 (s), 667 (m). UV-VIS (300 nm-800 nm, *l* = 1 cm, methanol, *c* = 1.14*10⁻³ mol*dm⁻³) $\lambda_{\text{max,Vis}}$: 556 nm, ϵ = 358 dm³*mol⁻¹*cm⁻¹. mp: 198-199°C (decomp.).



6-[1,3-Bis(*I'*R-1'-phenylethyl)-1,3-dihydro-imidazol-2-ylidene]-6H-[1,2,4,5]tetrazine-3-one (**3g**):

From 1.500 g (4.8 mmol) 1,3-bis(*I'*R-1'-phenylethyl)-imidazolium chloride (**2g**), 0.664 g (4.8 mmol) K₂CO₃ in 12 mL acetonitrile, and 1.300 g (4.8 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine in 12 mL acetonitrile we obtained 1.601 g **3g** (90% yield) as violet solid following column chromatography.


¹H NMR (250 MHz, CDCl₃) 7.63 (d, 2H, *J* = 1.5 Hz); 7.38-7.21 (m, 10H); 6.24 (q, 2H, *J* = 7.0 Hz); 1.945 (d, 6H, *J* = 7.0 Hz). ¹³C NMR (62.5 MHz, CDCl₃) 161.5; 144.6; 140.0; 137.4; 129.3; 129.3; 126.6; 120.1; 58.6; 20.7. HRMS (ESI-QTOF) calcd for [C₂₁H₂₁N₆O]⁺, [MH]⁺: 373.1771, found 373.1765, difference: -1.70 ppm. MS/MS (ESI, scan) *m/z* (%): 373 [MH⁺, 17%]; 269 [64%]; 165 [100%]. IR (KBr, cm⁻¹) 3117 (m), 2986 (m), 1992 (w), 1653 (vs), 1611 (vs), 1563 (s), 1490 (s), 1452 (s), 1383 (s), 1260 (m), 1225 (s), 1188 (m), 1104 (m), 1043 (w), 1027 (w), 823 (m), 760 (s), 741 (m), 700 (s), 611 (m), 558 (w), 525 (s), 418 (s). UV-VIS (300nm-800nm, *l* = 1 cm, methanol, *c* = 1.34*10⁻³ mol*dm⁻³) $\lambda_{\text{max,Vis}}$ = 557 nm, ϵ = 391 dm³*mol⁻¹*cm⁻¹. CD: (*l* = 1, 450-700 nm, acetonitrile, *c* = 1 mmol*dm⁻³) λ_{max} = 289 nm, (molar CD) Θ =20 dm³*mol⁻¹*cm⁻¹. mp: 182-183°C (decomp.).



6-(1,3-Dimethyl-1,3-dihydro-benzimidazol-2-ylidene)-6H-[1,2,4,5]tetrazin-3-one (3h):

From 135 mg (0.5 mmol) 1,3-dimethyl-benzimidazolium iodide (**2h**), 70 mg (0.5 mmol) K₂CO₃ in 4 mL acetonitrile, and 135 mg (0.5 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 4 mL acetonitrile we obtained 4 mg (3% yield) **3h** as violet solid after the work-up procedure. Because of the very poor solubility of **3h** in organic solvents, the purification was different from the generally applied column chromatography. The reaction mixture was evaporated, and the solid residue was washed with dichloromethane, ethylacetate, methanol and distilled water. All of the byproducts were removed in this way, and the solution of the remaining dark violet solid (**3h**) was concentrated enough for the ¹H NMR measurements, but not for ¹³C NMR.


¹H NMR (200 MHz, CD₃CN and D₂O): 7.92-7.86 (m, 2H); 7.76-7.70 (m, 2H); 4.11 (s, 6H) HRMS (ESI-QTOF) calcd for [C₁₁H₁₁N₆O]⁺, [MH]⁺: 243.0989, found 243.0990, difference: 0.4 ppm. MS (ESI, scan); *m/z* (%): 243 [MH⁺, 58%]; 172 [100%]. mp: 245-246°C (decomp.).



6-(1,3-Dibenzyl-1,3-dihydro-benzimidazol-2-ylidene)-6H-[1,2,4,5]tetrazin-3-one (3i):

From 168 mg (0.5 mmol) 1,3-dibenzyl-benzimidazolium chloride (**2i**), 70 mg (0.5 mmol) K₂CO₃ in 4 mL tetrahydrofuran, and 135 mg (0.5 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 4 mL tetrahydrofuran we obtained 46 mg **3i** (23% yield) as violet solid following column chromatography.


¹H NMR (250 MHz, d₆-DMSO) 7.92-7.86 (m, 2H), 7.67-7.62 (m, 2H), 7.34 (s, 10H), 6.01 (s, 4H) ¹³C NMR (62.9 MHz, CD₃OD and CDCl₃) 161.3; 145.3; 144.3; 132.7; 131.5; 128.8; 128.5; 127.6; 126.6; 113.4; 50.3. HRMS (ESI-QTOF) calcd for [C₂₃H₁₉N₆O]⁺, [MH]⁺: 395.1615, found 395.1610, difference: 1.2 ppm. MS/MS (ESI, scan); *m/z* (%): 395 [MH⁺, 44%]; 352 [19%]; 324 [100%]. IR (KBr, cm⁻¹) 3062 (w), 3027 (w), 2951 (w), 2015 (w), 1647 (vs), 1610 (vs), 1524 (s), 1498 (m), 1482 (m), 1465 (s), 1394 (m), 1267 (m), 1015 (m), 767 (s), 750 (s), 708 (m), 545 (w) cm⁻¹. UV-VIS (300 nm-800 nm, l = 1 cm, methanol, c = 5.02*10⁻⁴ mol*dm⁻³) $\lambda_{\text{max,Vis}}$: 558 nm, ε = 234 dm³*mol⁻¹*cm⁻¹. mp: 210-211°C (decomp.).



6-[1,3-Bis(1-phenylethyl)-1,3-dihydro-benzimidazol-2-ylidene]-6H-[1,2,4,5]tetrazin-3-one (3j):

From 204 mg (0.5 mmol) 1,3-bis(1-phenylethyl)-3H-benzimidazolium-bromide (**2j**), 70 mg (0.5 mmol) K₂CO₃ in 5 mL acetonitrile, and 135 mg (0.5 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 5 mL acetonitrile we obtained 110 mg **3j** (52% yield) as violet solid following column chromatography. **3j** was obtained as a mixture of diastereoisomers.

¹H NMR (250 MHz, CDCl₃ + CD₃OD) 7.26-7.23 (m, 14H), 6.13 (q, 2 H, *J* = 7.0 Hz), 2.03-2.00 (d, 6H, *J* = 7.0 Hz). ¹³C NMR (62.9 MHz, CDCl₃ + CD₃OD) 161.9, 161.9, 145.1, 145.0, 135.4, 135.4, 130.1, 129.1, 129.0, 128.9, 127.0, 126.4, 126.4, 115.0, 57.9, 17.7, 17.6. HRMS (ESI-QTOF) calcd for [C₂₅H₂₃N₆O]⁺, [MH]⁺: 423.1928, found 423.1939, difference: 2.5 ppm. MS (ESI, scan); *m/z* (%): 423 [MH⁺, 100%]; 343 [15%]. IR (KBr, cm⁻¹) 3109 (w), 3057 (w), 2986 (w), 2942 (w), 2016 (w), 1653 (vs), 1643 (vs), 1523 (m), 1498 (m), 1464 (vs), 1386 (s), 1263 (m), 1241 (m), 1080 (w), 1035 (m), 755 (s), 700 (m), 582 (w). UV-VIS (300 nm-800 nm, *l* = 1 cm, methanol, *c* = 8.99*10⁻⁴ mol*dm⁻³) $\lambda_{\text{max,Vis}}$: 554 nm, ϵ = 327 dm³*mol⁻¹*cm⁻¹. mp: 196-197°C (decomp.).




6-(1,3-Dibenzyl-1,3,3a,4,5,6,7,7a-octahydro-benzimidazol-2-ylidene)-6H-[1,2,4,5]tetrazin-3-one (3k):

From 197 mg (0.5 mmol) 1,3-dibenzyl-3a,4,5,6,7,7a-hexahydro-benzimidazolium tetrafluoroborate (**2k**), 70 mg (0.5 mmol) K₂CO₃ in 4 mL acetonitrile, and 136 mg (0.5 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 4 mL acetonitrile we obtained 84 mg **3k** (42% yield) as blue solid following column chromatography.

¹H NMR (250 MHz, d₆-DMSO and CD₃OD) 7.42-7.31 (m, 10.0H); 5.02 (d, 2H, *J* = 16.0 Hz); 4.77 (d, 2H, *J* = 16.5 Hz); 3.72 (d, 2H, *J* = 7.5 Hz); 2.01 (d, 2H, *J* = 11.0 Hz); 1.70 (d, 2H, *J* = 8.3 Hz); 1.35-1.27 (m, 2H); 1.27-1.18 (m, 2H). ¹³C NMR (62.9 MHz, 600 μL C₂H₄Cl₄ and 150 μL CDCl₃) 162.7; 144.95; 132.5; 129.2; 128.8; 127.3; 99.3; 66.9; 50.2; 27.6; 23.5. HRMS


(ESI-QTOF) calcd for $[C_{23}H_{25}N_6O]^+$, $[MH]^+$: 401.2084, found 401.2101, difference: 4.1 ppm. MS (ESI, scan) m/z (%): 401 [MH^+ , 70%], 330 [100%]. IR (KBr, cm^{-1}): 3027 (w), 2948 (m), 2869 (w), 2143 (w), 2004 (w), 1656 (vs), 1547 (vs), 1450 (m), 1385 (m), 1261 (s), 1180 (m), 1034 (w), 1001 (m), 818 (w), 728 (s), 691 (m), 564 (w), 465 (w). UV-VIS (300 nm-800 nm, $l = 1$ cm, methanol, $c = 4.48 \times 10^{-4}$ mol*dm $^{-3}$) $\lambda_{max,Vis}$: 558 nm, $\epsilon = 345$ dm $^3*\text{mol}^{-1}*\text{cm}^{-1}$. mp: 227-228 °C (decomp.).




6-(2,4,5-Triphenyl-2,4-dihydro-[1,2,4]triazol-3-ylidene)-6H-[1,2,4,5]tetrazine-3-one (3l):


From 193 mg (0.5 mmol) 1,3,4-triphenyl-4H-[1,2,4]triazolium tetrafluoroborate (**2l**), 70 mg (0.5 mmol) K_2CO_3 in 4 mL tetrahydrofuran, and 135 mg (0.5 mmol) 3,6-bis(3',5'-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, in 4 mL tetrahydrofuran we obtained 76 mg **3l** (39% yield) as violet solid following column chromatography.

1H NMR (250 MHz, d_6 -DMSO and CD_3CN) 7.72-7.47 (m, 15H). ^{13}C NMR (62.9 MHz, CD_3OD and $CDCl_3$) 162.7, 155.6, 148.7, 144.9, 136.7, 133.3, 132.8, 132.6, 132.2, 131.0, 130.7, 130.2, 129.9, 128.7, 126.2, 123.3. HRMS (ESI-QTOF) calcd for $[C_{22}H_{16}N_7O]^+$, $[MH]^+$: 394.1411, found 394.1414, difference: 0.7 ppm. MS/MS (ESI, scan); m/z (%): 395 [MH^+ , 100%]; 323 [41%]. IR (KBr, cm^{-1}): 3077 (w), 2025 (w), 1655 (vs), 1617 (s), 1540 (s), 1497 (s), 1445 (m), 1391 (s), 1269 (m), 1015 (m), 831 (w), 772 (m), 668 (s), 531 (m). UV-Vis (300 nm-800 nm, $l = 1$ cm, methanol, $c = 6.91 \times 10^{-4}$ mol*dm $^{-3}$) $\lambda_{max,Vis}$: 559 nm, $\epsilon = 278$ dm $^3*\text{mol}^{-1}*\text{cm}^{-1}$. mp: 230-231 °C (decomp.).







S16



3b


solvents: CDCl₃ and CD₃CN



S17

162.275
161.361
144.789
140.244
134.690
130.853
129.648

50.456
20.546
17.169



3b

Solvents: CDCl₃ and CD₃OD

CD₃OD

CDCl₃

25

50


75

100


125

150


175




S19




3c





3d

CDCl₃



S21

25

50

75

100

125

150


175

1.781
1.809

2.136
2.190

3.754
3.802
3.838
3.882
4.030
4.076
4.112
4.125
4.161
4.212
4.249
4.261
4.298
4.307
4.342
4.423
4.467
4.503
4.553

δ₂₂



3e

solvent: CDCl₃

6.798
6.760

7.393

5.0

2.0

1.0

3.0

3.0

3.0

2.0

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5


7.0

7.5

CDCl₃

CDCl₃


3e



160.959
160.895
144.468
139.776
136.232
135.202
131.539
129.588
129.573
129.150
128.908
126.930
S23

55.863
49.734
43.880
20.802
17.676
17.544
16.381






16.526

42.768

55.880

S25

CDCl₃



{R,R}

3f

129.268

129.078

126.995

136.275



144.234

161.165

159.923





S26





CDCI3

{R,R} solvent: CDCl₃





S29



H₂O


3i

solvent: d₆-DMSO

d₆-DMSO


1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0

1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0



1.995
2.004
2.023
2.033

6.0



3j

solvents: CDCl₃ + CD₃OD

S31

6.105
6.189
6.132
6.161

2.0

7.225
7.260


14.3



CDCl₃

CD₃OD

CD₃OD



8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0






S33


H₂O



3k


solvents: d₆-DMSO and CD₃OD





7.654
7.664
7.501
7.517
7.533
7.547
7.560
7.579
7.472
7.709
7.719

15.0



H₂O

d6-DMSO

3l

solvents: d6-DMSO and CD₃CN

